Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
1.050
-0.060 (-5.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
31
32
Next >
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
August 10, 2022
Via
ACCESSWIRE
The Power of Science to Stop a Killer
August 08, 2022
Via
Investor Brand Network
The Power of Science to Stop a Killer
August 08, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114...
Via
FinancialNewsMedia
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow
August 02, 2022
Via
Investor Brand Network
Topics
Cannabis
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow
August 02, 2022
Via
CannabisNewsWire
Topics
Cannabis
Intellectual Property
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
↗
July 27, 2022
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
July 27, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
July 27, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
↗
July 27, 2022
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4
Via
Benzinga
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
ACCESSWIRE
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent
July 25, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent
July 25, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market
July 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities
July 18, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities
July 18, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications
July 18, 2022
Via
CryptoCurrencyWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications
July 18, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book
July 14, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book
July 14, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 14, 2022
KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa
July 14, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
July 13, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
July 13, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria's Human Nicotine Study Nearing Start Date
July 13, 2022
Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry.
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Global Expansion of DehydraTECH Licensee
July 07, 2022
Via
Investor Brand Network
Topics
Intellectual Property
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
31
32
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today